

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

EXPRESS MAIL EL 990505256 US

No.:

APPLICANT(s): SATTLEGGER et al.

SERIAL NO.:

ART UNIT:

FILING DATE: Herewith

EXAMINER:

TITLE: SUBSTITUTED BENZO[B]AZEPIN-2-ONE COMPOUNDS

ATTORNEY

DOCKET NO.: 785-011767-US (PAR)

Mail Stop Patent Application

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

(37 C.F.R. §1.97(b)(1))

Sir:

This Information Disclosure Statement is filed together with the above-identified patent application. Thus, a certification under 37 C.F.R. 1.97 (e) or fee under 37 C.F.R. 1.17(p) is not required for the information herein to be considered.

The following information is being disclosed to the Patent and Trademark Office as information that may be

material to the examination of the above-identified patent application.

The above-identified patent application claims priority to German Patent Application No. 101 53 348.9 filed October 29, 2001 and claims the benefit of PCT International Application No. PCT/EP02/11830 filed October 23, 2002. Applicants' attorney encloses a copy of a German Search Report issued on the priority German Patent Application No. 101 53 348.9 and a PCT International Search Report issued on the corresponding PCT International Application No. PCT/EP02/11830.

Applicants' Attorney is aware of the following references:

US 3,475,414

US 5,733,936

WO 93/15059


The Merck Index (page 1506)

Copies of all references are enclosed together with a Form PTO-1449.

The filing of this Statement is not to be construed as a representation that a search has been made regarding the claimed invention (37 C.F.R. §1.97(g)) or that no other possible material information exists. In addition, the filing of this Information Disclosure Statement is not to be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability (37 C.F.R. §1.97(h)).

The Commissioner is hereby authorized to charge payment for any additional fees associated with this communication or credit any over payment to Deposit Account No. 16-1350.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Geza Ziegler", with a long horizontal flourish extending to the right. The signature is written over a horizontal line.

Geza C. Ziegler, Jr.

Reg. No.: 44,004

PERMAN & GREEN, LLP

425 Post Road, Fairfield, CT 06824

(203) 259-1800

Customer No.: 2512

14 April 2004

Date

**INFORMATION DISCLOSURE
CITATION FORM FOR
PATENT APPLICATION
(FORM PTO-1449)
(Substitute)**

Docket No.: 785-011767-US (PAR)

Serial No.:

Applicant(s): SATTLEGGGER et al.

Filing Date: Herewith

Group:

U.S. PATENTS

Initials	Patent Number	Issue Date	Name	Class	Sub-class	Filing date
	3,475,414 5,733,936	10/28/69 3/31/98	Havera et al. Buschmann et al.	260 514	239.3 646	
U.S. PATENT PUBLICATIONS						
Initials	Publication No.	Pub. Date	Name	Class	Sub-class	Filing Date

FOREIGN PATENT DOCUMENTS

Initials	Document Number	Date	Country	Name	Translation? Yes/No/n/a
	WO 93/15059	05.08.93	PCT	Pfizer Inc.	N/A

OTHER DOCUMENTS (Title, Author, Date, Pages, Etc., if known)

	Budavari, Susan, et al., "The Merck Index", Merck & Co., Inc., 1989, Nr. 9485, page 1506.

Examiner's Signature:

Date Considered:

Initial if reference was considered, whether or not citation is in conformance with MPEP. Mark through citation if not considered.
Include a copy of this citation form with your next correspondence to the Applicant(s).

Express Mail No.: EL 990505256 US

Customer No.: 2512